EGLN1 and pulmonary arterial hypertension: Mechanistically, we uncovered for the first time that AS-IV suppresses NLRP3-mediated pyroptosis and fibrosis in PASMCs through modulating the PHD2/HIF1α signaling pathway, thus restraining PAH progression (Fig. 6).